Psilocybin just cracked open a door that's been locked for 40 years — no drug has ever worked for cocaine use disorder until now. A UAB clinical trial published in JAMA Network Open showed psilocybin recipients had 29% more cocaine-abstinent days, with 30% achieving complete abstinence compared to zero in the placebo group. This is a durable, confirmed result across a deliberately diverse, low-income population that's been ignored by research for too long.
Psychedelic research has a serious credibility problem that can't be papered over with promising headlines. The FDA already rejected MDMA-assisted therapy, and a systematic review found high bias risk across nearly all psychedelic addiction and mental health trials. Rushing psilocybin toward approval before fixing these foundational research flaws risks repeating the same mistakes and harming the very vulnerable people these treatments claim to help.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.6.0